Literature DB >> 35399306

Tumour-associated Angiogenesis and Intermediate Blood Vessels in Renal Cell Carcinoma.

Marius Raica1, Anca Maria Cimpean1, Ovidiu Catalin Ferician2, Adela Maria Ferician2.   

Abstract

Background/Aim: Renal cell carcinoma is strongly vascularized, and formation of new blood vessels is a complex and multi-step process. In this study, we analysed the subtypes of intermediate blood vessels, as shown by double immunohistochemistry. Materials and
Methods: Tumour-associated blood vessels were identified by double immunostaining based on CD34 and smooth muscle cell actin. Blood vessels were classified both quantitatively and qualitatively based on the expression of the aforementioned two markers. The main criteria to sub-classify intermediate blood vessels was the presence, distribution, and arrangement of perivascular cells.
Results: We described three subtypes of intermediate blood vessels found particularly in the tumour area: Subtype 1 lacked perivascular cells, subtype 2 showed scattered pericytes attached to the vascular wall, and subtype 3 showed a continuous layer of perivascular cells on one side.
Conclusion: We describe for the first time three subtypes of renal cell carcinoma-associated intermediate blood vessels, which could be important in prognosis and as potential targets for anti-vascular therapy. Copyright 2021, International Institute of Anticancer Research.

Entities:  

Keywords:  CD34; Renal cell carcinoma; intermediate blood vessels; smooth muscle actin; tumor associated blood vessels

Year:  2021        PMID: 35399306      PMCID: PMC8962796          DOI: 10.21873/cdp.10031

Source DB:  PubMed          Journal:  Cancer Diagn Progn        ISSN: 2732-7787


  12 in total

1.  Distribution of Vascular Patterns in Different Subtypes of Renal Cell Carcinoma. A Morphometric Study in Two Distinct Types of Blood Vessels.

Authors:  Amparo Ruiz-Saurí; V García-Bustos; E Granero; S Cuesta; M A Sales; V Marcos; A Llombart-Bosch
Journal:  Pathol Oncol Res       Date:  2017-07-01       Impact factor: 3.201

Review 2.  Immunotherapeutic Targeting of Tumor-Associated Blood Vessels.

Authors:  Kellsye L Fabian; Walter J Storkus
Journal:  Adv Exp Med Biol       Date:  2017       Impact factor: 2.622

Review 3.  Tumor angiogenesis: therapeutic implications.

Authors:  J Folkman
Journal:  N Engl J Med       Date:  1971-11-18       Impact factor: 91.245

4.  Heterogeneous vascular patterns in renal cell carcinomas.

Authors:  O Ferician; A M Cimpean; A R Ceausu; A Dema; M Raica; A Cumpanas
Journal:  Pol J Pathol       Date:  2016-03       Impact factor: 1.072

Review 5.  Angiogenesis.

Authors:  Judah Folkman
Journal:  Annu Rev Med       Date:  2006       Impact factor: 13.739

6.  Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumour growth in vivo.

Authors:  K J Kim; B Li; J Winer; M Armanini; N Gillett; H S Phillips; N Ferrara
Journal:  Nature       Date:  1993-04-29       Impact factor: 49.962

7.  DLK1: a novel target for immunotherapeutic remodeling of the tumor blood vasculature.

Authors:  Nina Chi Sabins; Jennifer L Taylor; Kellsye P L Fabian; Leonard J Appleman; Jodi K Maranchie; Donna Beer Stolz; Walter J Storkus
Journal:  Mol Ther       Date:  2013-07-30       Impact factor: 11.454

8.  Tyrosine kinase inhibitor-induced vasculopathy in clear cell renal cell carcinoma: an unrecognized antitumour mechanism.

Authors:  Toyonori Tsuzuki; Naoto Sassa; Yoshie Shimoyama; Takamitsu Morikawa; Ryoichi Shiroki; Makoto Kuroda; Akitoshi Fukatsu; Kyoko Kuwahara; Yasushi Yoshino; Ryohei Hattori; Momokazu Gotoh
Journal:  Histopathology       Date:  2013-11-26       Impact factor: 5.087

9.  Sunitinib acts primarily on tumor endothelium rather than tumor cells to inhibit the growth of renal cell carcinoma.

Authors:  Dan Huang; Yan Ding; Yan Li; Wang-Mei Luo; Zhong-Fa Zhang; John Snider; Kristin Vandenbeldt; Chao-Nan Qian; Bin Tean Teh
Journal:  Cancer Res       Date:  2010-01-26       Impact factor: 12.701

10.  Tumor vessel development and maturation impose limits on the effectiveness of anti-vascular therapy.

Authors:  Michael S Gee; William N Procopio; Sosina Makonnen; Michael D Feldman; Newman M Yeilding; William M F Lee
Journal:  Am J Pathol       Date:  2003-01       Impact factor: 4.307

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.